Clinical Scorecard: Creation and assessment of a predictive framework for optimizing plerixafor administration in children

At a Glance

Key Highlights

• Plerixafor combined with G-CSF improves mobilization success rates in pediatric patients compared to G-CSF alone.
• A strong linear correlation (r=0.84) exists between peripheral blood CD34+ counts prior to apheresis and CD34+ cells collected.
• Predictive modeling can optimize timing and use of plerixafor to enhance stem cell collection efficiency in children.

Guideline-Based Recommendations

Diagnosis

• Assess peripheral blood CD34+ cell counts prior to apheresis to predict stem cell harvest yield.

Management

• Use plerixafor in combination with G-CSF for pediatric patients who are poor mobilizers or predicted to have insufficient stem cell yield.
• Administer plerixafor approximately 10 hours before apheresis to achieve peak mobilization.

Monitoring & Follow-up

• Monitor peripheral blood CD34+ counts on the day of apheresis to guide mobilization success and need for further intervention.

Risks

• Consider potential mobilization failure with G-CSF alone (8–27% failure rate) and use plerixafor to reduce this risk.

Patient & Prescribing Data

Pediatric patients aged 1 to <18 years with lymphoma or solid tumors eligible for autologous transplant

In the MOZAIC trial, 80% of patients receiving plerixafor plus G-CSF met the primary endpoint of doubling peripheral blood CD34+ counts versus 28.6% with G-CSF alone.

Clinical Best Practices

• Incorporate predictive models based on peripheral blood CD34+ counts to optimize timing and dosing of plerixafor.
• Limit apheresis to a single day in most pediatric patients to reduce resource utilization while ensuring adequate stem cell collection.
• Use plerixafor preemptively in patients with predicted insufficient mobilization to improve collection outcomes.

References

• MOZAIC Trial Clinical Study
• Plerixafor US FDA Approval
• European Medicines Agency Plerixafor Indications